Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/femspd/ftaa025 http://scihub22266oqcxt.onion/10.1093/femspd/ftaa025 32510562!7314002!32510562     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pathog+Dis 2020 ; 78 (3): ä Nephropedia Template TP {{tp|p=32510562|t=2020. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge |pdf=|usr=}}{{32510562}} gab.com Text Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge JO: Pathog Dis http://www.kidney.de/pget.php?&tw=1&pmid=32510562 #FOAvip Effective herd immunity against SARS-CoV-2 will be determined on many factors: the percentage of the immune population, the length and effectiveness of the immune response and the stability of the viral epitopes. The required percentage of immune individuals has been estimated to be 50-66% of the population which, given the current infection rates, will take long to be achieved. Furthermore, data from SARS-CoV suggest that the duration of immunity may not be sufficiently significant, while the immunity response against SARS-CoV-2 may not be efficiently effective in all patients, as relapses have already been reported. In addition, the development of mutant strains, which has already been documented, can cause the reemergence of the epidemic. In conclusion, the development of an effective vaccine is an urgent necessity, as long-term natural immunity to SARS-CoV-2 may not be sufficient for the control of the current and future outbreaks. Twit Text FOAVip Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge ????Pathog Dis http://www.kidney.de/pget.php?&tw=1&pmid=32510562 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32510562 #FOAvip English Wikipedia <ref>{{Cite pmid|32510562}}</ref> Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge #MMPMID32510562 Papachristodoulou E; Kakoullis L; Parperis K; Panos G Pathog Dis 2020[Apr]; 78 (3): ä PMID32510562show ga Effective herd immunity against SARS-CoV-2 will be determined on many factors: the percentage of the immune population, the length and effectiveness of the immune response and the stability of the viral epitopes. The required percentage of immune individuals has been estimated to be 50-66% of the population which, given the current infection rates, will take long to be achieved. Furthermore, data from SARS-CoV suggest that the duration of immunity may not be sufficiently significant, while the immunity response against SARS-CoV-2 may not be efficiently effective in all patients, as relapses have already been reported. In addition, the development of mutant strains, which has already been documented, can cause the reemergence of the epidemic. In conclusion, the development of an effective vaccine is an urgent necessity, as long-term natural immunity to SARS-CoV-2 may not be sufficient for the control of the current and future outbreaks. |*Immunity, Herd[MESH] |Betacoronavirus/*immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/epidemiology/*immunology/*virology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/epidemiology/*immunology/*virology[MESH] |SARS-CoV-2[MESH]Long-term and herd immunity against SARS-CoV-2: implications from curr(epmc).pdf DeepDyve Pubget Overpricing